Escitalopram for ASD and PTSD Prevention in Trauma Victims

Phase 3, randomised, double-blind trial of escitalopram in acute stress disorder (ASD), post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoints: Acute Stress Disorder symptoms at 12 weeks and Post-Traumatic Stress Disorder symptoms at 12 weeks. Started Jun 2005; status: terminated.